We scan new podcasts and send you the top 5 insights daily.
Dr. Patel notes that molecular testing is now easier by liquid biopsy, while IHC remains a serial process on limited tissue. When tissue is scarce, he suggests using liquid biopsy up front for diagnosis or NGS and saving the biopsy for PD-L1, MET, and HER2 stains.
Positioning non-invasive tests to complement rather than replace gold-standard invasive procedures accelerates clinical integration. By filtering out low-risk cases, liquid biopsies eliminate diagnostic bottlenecks and expedite invasive interventions for patients with verified molecular signatures of malignancy.
Unlike invasive tissue biopsies that sample a single site, liquid blood biopsies provide a comprehensive, real-time snapshot of mutations across all metastatic sites. This is crucial for identifying acquired mutations and guiding timely treatment decisions.
For certain therapies like Enhertu, eligibility is based on immunohistochemistry (IHC), not NGS. Labs must run HER2 IHC in parallel because NGS, as a population-based test, can miss intratumoral heterogeneity (small clusters of positive cells) that IHC can detect, thus identifying more eligible patients for targeted therapy.
Oncologists co-order tissue and liquid biopsies for new pancreatic cancer patients. This is crucial because tissue samples are insufficient for genomic testing in roughly 20% of cases, making the liquid biopsy an essential backup for treatment planning.
In gastroesophageal adenocarcinoma, treatment decisions and pivotal clinical trials rely on HER2 status determined by tissue IHC and ISH testing. While liquid biopsy (ctDNA) is used in other cancers, it is not considered an interchangeable or recommended surrogate for tissue-based analysis in this specific disease, and should only be used when a tissue biopsy is not feasible.
Patients with HER2-positive GI cancers can lose expression after treatment. While re-biopsy is ideal, it's often impractical or risky. In these cases, clinicians find ctDNA analysis of HER2 copy numbers to be a reliable alternative for guiding subsequent treatment decisions.
Liquid biopsies are superior for ESR1 testing because the mutation is subclonal and develops under therapy pressure. A tissue biopsy from one metastatic site can miss the mutation, while circulating tumor DNA (ctDNA) from a blood sample aggregates genetic material from all sites, increasing detection rates.
Despite the risk of missing mutations, oncologists predominantly use convenient, less-invasive liquid biopsies to test for biomarkers at disease progression. A more invasive tissue biopsy is generally reserved for situations where the cancer behaves unexpectedly, such as a sudden shift from bone-only to visceral disease, which might suggest a missed biological driver.
Performing dual analysis with both liquid and tissue biopsies at metastatic diagnosis establishes a comprehensive baseline. This strategy helps differentiate between clonal and later-acquired mutations, enabling more accurate interpretation of subsequent ctDNA monitoring for resistance.
To prevent exhausting small tissue samples, a pathology lab physically splits incoming biopsies into two cassettes. A small portion is used for initial diagnostic workups like immunohistochemical stains, while the bulk of the specimen is reserved in a separate cassette specifically for molecular testing, guaranteeing tissue adequacy.